{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:13:20Z","timestamp":1793211200614,"version":"4.5.0"},"reference-count":19,"publisher":"Harborside Press, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> NCCN Guidelines for Hematopoietic Growth Factors recommend evaluation and treatment of anemia in patients with cancer. However, a paucity of data exists regarding compliance with these recommendations. <jats:bold>Methods:<\/jats:bold> A retrospective cohort study was performed of patients diagnosed with any solid tumor at Vanderbilt University Medical Center from 2008 to 2017. Tumor registry\u2013confirmed cancer cases were identified by ICD-O codes using the Synthetic Derivative database. Anemia was defined as hemoglobin (Hgb) level \u226411 g\/dL and graded according to CTCAE version 5.0. Absolute, functional, and possible functional iron deficiency were defined based on NCCN Guidelines. <jats:bold>Results:<\/jats:bold> A total of 25,018 patients met inclusion criteria. Median age was 60 years. The most common malignancies were respiratory tract, prostate, and nonprostate urologic (11% each). Among 8,695 patients with Hgb levels available prior to diagnosis, 1,484 (17%) were noted to be anemic proximal to diagnosis. Of the 25,018 patients, 11,019 (44%) were anemic within 6 months of diagnosis. Of these patients, 4,686 (43%) had grade 2 (moderate) anemia and 9,623 (87%) had normocytic anemia. Patients with retroperitoneal\/peritoneal cancers had the highest prevalence of anemia (83\/110; 75%). A total of 4,125 (37%) underwent any evaluation of their anemia, of whom 1,742 (16%) had iron studies performed and 1,528 (14%) had vitamin B<jats:sub>12<\/jats:sub> or folate studies performed. Fewer than half of patients with anemia received treatment (n=4,318; 39%), including blood transfusion (n=3,528; 32%), oral iron supplementation (n=1,279; 12%), or intravenous iron supplementation (n=97; 1%). Anemia treatment was significantly more frequent as the grade of anemia increased (any treatment among grade 1\/mild: 12%; grade 2\/moderate: 31%; grade 3\/severe: 77%; \u03c7<jats:sup>2<\/jats:sup> [2, n=11,019]=3,020.6; <jats:italic>P<\/jats:italic>&lt;.001). Patients with penile and testicular cancers had the highest prevalence of anemia evaluation (n=57; 79%). <jats:bold>Conclusions:<\/jats:bold> Anemia is common in patients with solid tumors; yet, compliance with NCCN Guidelines for evaluation and treatment of anemia remains low. There are opportunities to improve compliance with guidelines across the spectrum of cancer care.<\/jats:p>","DOI":"10.6004\/jnccn.2023.7108","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T19:10:32Z","timestamp":1710529832000},"source":"Crossref","is-referenced-by-count":6,"title":["Compliance With NCCN Guidelines for Evaluation and Treatment of Anemia Among Patients With Solid Tumors"],"prefix":"10.6004","volume":"22","author":[{"given":"Demetra Hypatia","family":"Hufnagel","sequence":"first","affiliation":[{"name":"Vanderbilt University School of Medicine, Nashville, TN"},{"name":"Department of Obstetrics and Gynecology, University of California, Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia Manfredi","family":"Bos","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaina Johnson","family":"Brown","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren Shore","family":"Prescott","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Am J Med","first-page":"11S","article-title":"Prevalence and outcomes of anemia in cancer: a systematic review of the literature","volume":"116","author":"Knight K","year":"2004","unstructured":"Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;116(Suppl 7A):11S\u201326S."},{"key":"B2","series-title":"Oncology","first-page":"3","article-title":"Cancer-related anemia: pathogenesis, prevalence and treatment","volume":"68","author":"Birgeg\u00e5rd G","year":"2005","unstructured":"Birgeg\u00e5rd G, Aapro MS, Bokemeyer C,  Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005;68(Suppl 1):3\u201311."},{"key":"B3","series-title":"Cancer","first-page":"2214","article-title":"Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review","volume":"91","author":"Caro JJ","year":"2001","unstructured":"Caro JJ, Salas M, Ward A,  Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214\u20132221."},{"key":"B4","article-title":"NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors","author":"Becker PS","unstructured":"Becker PS, Griffiths EA, Alwan L. NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors. Version 2.2023. Accessed November 1, 2023. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B5","series-title":"Am J Hematol","first-page":"203","article-title":"Diagnosis and treatment of cancer-related anemia","volume":"89","author":"Gilreath JA","year":"2014","unstructured":"Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer-related anemia. Am J Hematol 2014;89:203\u2013212."},{"key":"B6","series-title":"Gynecol Oncol","first-page":"597","article-title":"Choosing wisely: decreasing the incidence of perioperative blood transfusions in gynecologic oncology","volume":"153","author":"Prescott LS","year":"2019","unstructured":"Prescott LS, Taylor JS, Enbaya A,  Choosing wisely: decreasing the incidence of perioperative blood transfusions in gynecologic oncology. Gynecol Oncol 2019;153:597\u2013603."},{"key":"B7","series-title":"J Natl Compr Canc Netw","first-page":"513","article-title":"Prevalence of anemia and compliance with NCCN Guidelines for evaluation and treatment of anemia in patients with gynecologic cancer","volume":"19","author":"Hufnagel DH","year":"2021","unstructured":"Hufnagel DH, Mehta ST, Ezekwe C,  Prevalence of anemia and compliance with NCCN Guidelines for evaluation and treatment of anemia in patients with gynecologic cancer. J Natl Compr Canc Netw 2021;19:513\u2013520."},{"key":"B8","series-title":"Clin Pharmacol Ther","first-page":"362","article-title":"Development of a large-scale de-identified DNA biobank to enable personalized medicine","volume":"84","author":"Roden DM","year":"2008","unstructured":"Roden DM, Pulley JM, Basford MA,  Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther 2008;84:362\u2013369."},{"key":"B9","article-title":"Common terminology criteria for adverse events (CTCAE)","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Accessed March 1, 2020. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"B10","series-title":"Pharmaceuticals (Basel)","first-page":"94","article-title":"Anemia and iron deficiency in cancer patients: role of iron replacement therapy","volume":"11","author":"Busti F","year":"2018","unstructured":"Busti F, Marchi G, Ugolini S,  Anemia and iron deficiency in cancer patients: role of iron replacement therapy. Pharmaceuticals (Basel) 2018;11:94."},{"key":"B11","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"14","article-title":"Understanding anemia of chronic disease","volume":"2015","author":"Fraenkel PG.","year":"2015","unstructured":"Fraenkel PG. Understanding anemia of chronic disease. Hematology Am Soc Hematol Educ Program 2015;2015:14\u201318."},{"key":"B12","series-title":"Eur J Cancer","first-page":"2293","article-title":"The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients","volume":"40","author":"Ludwig H","year":"2004","unstructured":"Ludwig H, Van Belle S, Barrett-Lee P,  The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293\u20132306."},{"key":"B13","series-title":"Clin Epidemiol","first-page":"61","article-title":"Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010\u20132013","volume":"8","author":"Xu H","year":"2016","unstructured":"Xu H, Xu L, Page JH,  Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010\u20132013. Clin Epidemiol 2016;8:61\u201371."},{"key":"B14","series-title":"Ann Oncol","first-page":"1886","article-title":"Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia","volume":"24","author":"Ludwig H","year":"2013","unstructured":"Ludwig H, M\u00fcld\u00fcr E, Endler G,  Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 2013;24:1886\u20131892."},{"key":"B15","series-title":"Ann Oncol","first-page":"iv96","article-title":"Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines","volume":"29","author":"Aapro M","year":"2018","unstructured":"Aapro M, Beguin Y, Bokemeyer C,  Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. Ann Oncol 2018;29(Suppl 4):iv96\u2013110."},{"key":"B16","series-title":"Gynecol Oncol","first-page":"522","article-title":"Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy","volume":"116","author":"Dangsuwan P","year":"2010","unstructured":"Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010;116:522\u2013525."},{"key":"B17","series-title":"Gynecol Oncol","first-page":"199","article-title":"Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy","volume":"105","author":"Kim YT","year":"2007","unstructured":"Kim YT, Kim SW, Yoon BS,  Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007;105:199\u2013204."},{"key":"B18","series-title":"Ann Oncol","first-page":"475","article-title":"Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia","volume":"24","author":"Steinmetz T","year":"2013","unstructured":"Steinmetz T, Tschechne B, Harlin O,  Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 2013;24:475\u2013482."},{"key":"B19","series-title":"Acta Haematol","first-page":"13","article-title":"The role of intravenous iron in the treatment of anemia associated with cancer and chemotherapy","volume":"142","author":"Rodgers GM","year":"2019","unstructured":"Rodgers GM, Gilreath JA. The role of intravenous iron in the treatment of anemia associated with cancer and chemotherapy. Acta Haematol 2019;142:13\u201320."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/3\/article-e237108.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/3\/article-e237108.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/3\/article-e237108.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T20:12:00Z","timestamp":1713298320000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/3\/article-e237108.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":19,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2023.7108","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}